Home

The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).

SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. For example, the Group significantly contributed to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.


Visitors and news

Training course on the role of low-cost portable magnifying device and colposcopy in the early detection and prevention of cervical cancer, Lusaka, Zambia

18/03/2019 – 23/03/2019
Dr Partha Basu and Dr Srabani Mittal conducted this practical training course to train the trainers within the framework of the project “Diagnostic test accuracy of the low-cost portable magnifying device mobile colposcope in HIV-positive women in Zambia” in collaboration with the Department of Reproductive, Maternal, Newborn, and Child Health at the Centre for Infectious Disease Research in Zambia (CIDRZ), and the Institute of Social and Preventive Medicine (ISPM), Switzerland.

Field visit for the Delta project, Lusaka, Zambia

22/03/2019
Dr Partha Basu visited the Delta office in the Centre for Infectious Disease Research to discuss the progress with the local team of the ongoing United States National Cancer Institute-funded project “Randomized controlled trial of the Liger Thermal Coagulator versus cryosurgery and versus large loop excision of the transformation zone (LLETZ) to prevent cervical neoplasia in VIA-positive women in low- and middle-income countries”.

Registration for the virtual seminar: Cervical cancer prevention

18/03/2019
Dr Partha Basu will be talking the 2 April at 16:00 CET about the timely topic of cervical cancer prevention (Recommendations of the European Code Against Cancer, Towards elimination of cervical cancer: WHO call to action, State of play in Europe: screening & vaccination and Global impact of cervical cancer prevention) within the framework of the association of the European Cancer Leagues (ECL) and the European Code Against Cancer (ECAC). The webinar is open for registration: Registration for the webinar.

All visitors and news


Scientific papers

Gadgil A., Sauvaget C., Roy N., Muwonge R., Lucas E., Sankaranarayanan R. Setting up a Breast Cancer Awareness Project in Mumbai: Methodology, Experiences and Challenges. J Cancer Educ. 2019 Mar 12. doi: 10.1007/s13187-019-01500-x.
PMID: 30863980
Randall T.C., Sauvaget C., Muwonge R., Trimble E.L., Jeronimo J. Authors response to Papoutsis and colleagues letter to the editor regarding: Worthy of further consideration: An updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Prev Med. 2019 Feb 10.
PMID: 30759368
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow up cohort study. Basu P., Muwonge R., Bhatla N., Nene B.M., Joshi S., Esmy P.O., Poli U.R.R., Joshi G., Verma Y., Zomawia E., Shastri S.S., Pimple S., Anantharaman D., Prabhu P.R., Hingmire S., Sauvaget C., Lucas E., Pawlita M., Gheit T., Jayant K., Malvi S.G., Siddiqi M., Michel A., Butt J., Sankaran S., Rameshwari Ammal Kannan T.P., Varghese R., Divate U., Willhauck-Fleckenstein M., Waterboer T., Muller M., Sehr P., Vashist S., Mishra G., Jadhav R., Thorat R., Tommasino M., Pillai M.R., Sankaranarayanan R.; Indian HPV vaccine study group. Papillomavirus Res. 2019 Jan 31. pii: S2405-8521(18)30133-2.
PMID: 30711698

All scientific papers

IARC, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France - Tel: +33 (0)4 72 73 84 85 - Fax: +33 (0)4 72 73 85 75
© IARC 2019 - All Rights Reserved.